Large Inflow of Money Witnessed in Gilead Sciences

Gilead Sciences (NASDAQ:GILD) had a weak trading session and its shares were last down at $82.67, down -0.32% or -0.39 points. The trading data also revealed that the total net flow stood at $7 million as the shares had $13.63 million in upticks but lost $6.64 million in downticks. The up/down ratio was 2.05. This data is particularly important for the traders and speculators alike as it could also be used to gauge the strength of the momentum in the shares. During the past week, the shares have seen a change of 0.02% in the shares.The block trade data suggests an inflow of $8.05 million in upticks and an outflow of $0.92 million in downticks. The up/down ratio for the block stood at 8.78. The net money flow for this transaction was recorded at $7.14.


The stock has recorded a 20-day Moving Average of 3.72% and the 50-Day Moving Average is 7.68%. The company shares have dropped 32.09% in the past 52 Weeks. On June 24, 2015 The shares registered one year high of $123.37 and one year low was seen on May 19, 2016 at $81.28. The 50-day moving average is $84.96 and the 200 day moving average is recorded at $91.71. S&P 500 has rallied 1.93% during the last 52-weeks.

Gilead Sciences (NASDAQ:GILD): The stock opened at $83.35 on Tuesday but the bulls could not build on the opening and the stock topped out at $83.44 for the day. The stock traded down to $81.43 during the day, due to lack of any buying support eventually closed down at $81.79 with a loss of -1.45% for the day. The stock had closed at $82.99 on the previous day. The total traded volume was 8,411,995 shares.

Currently the company Insiders own 1.4% of Gilead Sciences shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -6.2% . Institutional Investors own 81.8% of Gilead Sciences shares. During last six month period, the net percent change held by insiders has seen a change of -9.29%. On the companys insider trading activities,The director officer (President and CEO) of Gilead Sciences Inc, Milligan John F sold 112,000 shares at $86.92 on June 6, 2016. The Insider selling transaction had a total value worth of $9,735,040. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.

Gilead Sciences, Inc. (Gilead), is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, oncology and inflammation, and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. Its Liver Diseases products include Harvoni, Sovaldi, Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.